PTC Therapeutics stock forecast
PTC Therapeutics (P91) Stock Forecast & Price Target
P91 Analyst Ratings
P91 Stock 12 Month Forecast
Average Price Target
CHF84.08▲(0.00% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Brian Cheng | J.P. Morgan | CHF77.35 | buy | ― | Reiterated | 11/05/26 | ||
| Eliana Merle | Barclays | CHF102.57 | buy | ― | Reiterated | 11/02/26 | ||
| Eric Joseph | Citi | CHF90.80→CHF91.64 | buy | ― | Reiterated | 11/02/26 | ||
| Joon Lee | UBS | CHF75.67 | buy | ― | Reiterated | 10/30/26 | ||
| Benjamin Burnett | Wells Fargo | CHF91.64→CHF94.16 | buy | ― | Reiterated | 10/30/26 | ||
| Joseph Thome | TD Cowen | CHF75.67→CHF79.87 | buy | ― | Reiterated | 10/30/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 10/30/26 | ||
| Brian Abrahams | RBC Capital | CHF63.06→CHF64.74 | hold | ― | Reiterated | 10/29/26 | ||
| Kristen Kluska | Cantor Fitzgerald | CHF115.18 | buy | ― | Reiterated | 10/29/26 | ||
| Tiago Fauth | Raymond James | CHF90.80→CHF89.12 | buy | ― | Reiterated | 10/20/26 | ||
| Truist Financial | CHF52.13 | hold | ― | Initiated | 10/16/26 | |||
| Basma Radwan | Leerink Partners | CHF58.85→CHF82.39 | buy | ― | Initiated | 09/14/26 | ||
| Judah Frommer | Morgan Stanley | CHF78.19→CHF87.44 | buy | ― | Reiterated | 07/31/26 | ||
| Paul Choi | Goldman Sachs | CHF58.85 | sell | ― | Reiterated | 07/30/26 | ||
| Faisal Khurshid | Jefferies | CHF63.90→CHF71.46 | buy | ― | Upgraded | 05/27/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Brian ChengJ.P. Morgan | BuyReiteratedCHF77.35 | 11/05/26 | ― | ||
| Eliana MerleBarclays | BuyReiteratedCHF102.57 | 11/02/26 | ― | ||
| Eric JosephCiti | BuyReiteratedCHF90.80→CHF91.64 | 11/02/26 | ― | ||
| Joon LeeUBS | BuyReiteratedCHF75.67 | 10/30/26 | ― | ||
| Benjamin BurnettWells Fargo | BuyReiteratedCHF91.64→CHF94.16 | 10/30/26 | ― | ||
| Joseph ThomeTD Cowen | BuyReiteratedCHF75.67→CHF79.87 | 10/30/26 | ― | ||
| Tazeen AhmadBank of America Securities | BuyReiterated | 10/30/26 | ― | ||
| Brian AbrahamsRBC Capital | HoldReiteratedCHF63.06→CHF64.74 | 10/29/26 | ― | ||
| Kristen KluskaCantor Fitzgerald | BuyReiteratedCHF115.18 | 10/29/26 | ― | ||
| Tiago FauthRaymond James | BuyReiteratedCHF90.80→CHF89.12 | 10/20/26 | ― | ||
| HoldInitiatedCHF52.13 | 10/16/26 | ― | |||
| Basma RadwanLeerink Partners | BuyInitiatedCHF58.85→CHF82.39 | 09/14/26 | ― | ||
| Judah FrommerMorgan Stanley | BuyReiteratedCHF78.19→CHF87.44 | 07/31/26 | ― | ||
| Paul ChoiGoldman Sachs | SellReiteratedCHF58.85 | 07/30/26 | ― | ||
| Faisal KhurshidJefferies | BuyUpgradedCHF63.90→CHF71.46 | 05/27/26 | ― |
Best Analysts Covering PTC Therapeutics
Copying Tiago Fauth's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +15.01% per trade.
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +46.40% per trade.
Copying Sami Corwin's trades and holding each position for 2 Years would result in 85.19% of your transactions generating a profit, with an average return of +60.08% per trade.
P91 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 7 | 9 | 11 | 14 | 13 |
| Buy | 14 | 10 | 10 | 6 | 5 |
| Hold | 5 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 27 | 23 | 25 | 23 | 21 |
In the current month, P91 has received 18 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. P91 average Analyst price target in the past 3 months is 84.08.
P91 Financial Forecast
P91 Earnings Forecast
Next quarter’s earnings estimate for P91 is CHF 0.28 with a range of -CHF 0.35 to CHF 0.74. The previous quarter’s EPS was -CHF 0.51. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
P91 Sales Forecast
Next quarter’s sales forecast for P91 is CHF 270.83M with a range of CHF 248.61M to CHF 285.27M. The previous quarter’s sales results were CHF 293.31M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

